IMPRiND Project

IMPRiND partner Outeiro at Nature Neuroscience: Novel protein interactions explain memory deficits in Parkinson’s disease

IMPRiND partner Tiago Outeiro, Director of the Department of Experimental Neurodegeneration and his team at the University Medical Center Goettingen (UMG), Germany has just published a study in the journal Nature Neuroscience, from Nature publishing group, describing the identification of a novel molecular pathway that can constitute a therapeutic target for cognitive defects in Parkinson’s disease.

It has been shown that abnormal forms of Parkinson’s disease (PD)-associated protein alpha-synuclein interact with the prion protein (PrP), triggering a cascade of events that culminates in neuronal dysfunction, causing cognitive defects that are reminiscent of those in PD.
“This is the follow up of a previous study initiated in my laboratory, where we found that particular forms of the protein alpha-synuclein cause dysfunction of neuronal circuits involved in memory formation. We did not know how this was happening, and in this new study we have detailed the molecular mechanisms involved, which suggests we now have new targets for therapeutic intervention” – explains Tiago Outeiro.

IMPRIND partner Heutink in Science, further supporting the notion that modulating synuclein levels matters in PD​.

A new study with IMPRIND partner Heutink, published in Science, further supports the notion that modulating synuclein levels matters in PD.

IMPRiND full website published today

The IMPRiND full website has been published today. It will be regularly updated with news about the project, results, events etc. Please stay tuned!

Show more posts

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.